Nutra Group LLC Risk Report

⚖️ Legal & Regulatory

The company appears to be involved in several regulatory and compliance-related activities. These events denote important changes and challenges they may face in the regulatory landscape. Key issues include regulatory reviews and compliance activities, with a significant impact on operations.

• Indian authorities banned 'new drugs,' including nutra formulations 🗓 2025-05-07, indicating stricter regulations which may affect the company's product offerings in the region.
• A regulatory review in China and Taiwan, focusing on import policies and vitamin B12 precautions, took place 🗓 2025-02-21, suggesting potential regulatory hurdles in these markets.
• New nutra regulations came into force in 2025 🗓 2025-01-07, impacting business activities and compliance requirements.

👥 Labor & Workforce

Labor and workforce adjustments are evident within the company, which can signal changes in strategy, expansion, or contraction efforts. The company is noted for its active hiring or career movements.

• New nutra jobs were announced 🗓 2025-03-20 for the winter 2024-2025 period, reflecting potential growth or strategic employment initiatives.
• Summer 2024 saw a movement of personnel with new nutra jobs being reported 🗓 2024-09-23, indicating a dynamic workforce environment.

📜 Innovation & R&D

Continuous efforts in innovation and R&D demonstrate the company's commitment to staying ahead in the market. The company is focusing on improving and refining products with new technologies and methodologies.

• AI for nutra was highlighted with opportunities arising in finding supporting evidence and refining products 🗓 2025-03-10, marking advancements in product development.
• L-Nutra introduced a new iteration of the ProLon® 5-Day Fasting Mimicking Diet program 🗓 2025-03-27, showcasing the ongoing R&D in dietary solutions.